Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
European Journal of Medicinal Chemistry|December 31, 2015
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptorsStephanie Federico, Antonella Ciancetta, Nicola Porta, et al.Plos One|December 2, 2015
The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine DerivativesStephanie Federico, Sara Redenti, Mattia Sturlese, et al.Journal of Medicinal Chemistry|October 27, 2012
Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonistsStephanie Federico, Antonella Ciancetta, Davide Sabbadin, et al.Journal of Chemical Information and Modeling|November 14, 2009
Exploring potency and selectivity receptor antagonist profiles using a multilabel classification approach: the human adenosine receptors as a key studyLisa Michielan, Federico Stephanie, Lothar Terfloth, et al.Journal of Medicinal Chemistry|June 28, 2014
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: a preliminary structure-activity relationship studyStephanie Federico, Antonella Ciancetta, Nicola Porta, et al.European Journal of Medicinal Chemistry|November 6, 2013
8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligandsDiego Dal Ben, Michela Buccioni, Catia Lambertucci, et al.Journal of Chemical Information and Modeling|January 25, 2008
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptorLisa Michielan, Magdalena Bacilieri, Andrea Schiesaro, et al.Molecular Pharmaceutics|February 2, 2012
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approachAlessandro Dalpiaz, Barbara Cacciari, Chiara Beatrice Vicentini, et al.Journal of Medicinal Chemistry|January 7, 2005
Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key studyStefano Moro, Paolo Braiuca, Francesca Deflorian, et al.Current Pharmaceutical Design|October 9, 2002
Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes?Pier Giovanni Baraldi, Barbara Cacciari, Pier Andrea Borean, et al.Pageof 5